StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY – Free Report) in a research note issued to investors on Tuesday. The brokerage issued a sell rating on the stock.
NovaBay Pharmaceuticals Price Performance
NovaBay Pharmaceuticals stock opened at $0.08 on Tuesday. The firm has a market cap of $2.84 million, a price-to-earnings ratio of -0.02 and a beta of 1.97. The business’s 50-day moving average price is $0.12 and its 200 day moving average price is $0.21. NovaBay Pharmaceuticals has a 52 week low of $0.07 and a 52 week high of $1.42.
NovaBay Pharmaceuticals (NYSE:NBY – Get Free Report) last issued its quarterly earnings results on Tuesday, March 26th. The company reported ($0.95) earnings per share (EPS) for the quarter. The business had revenue of $3.73 million for the quarter. NovaBay Pharmaceuticals had a negative return on equity of 150.14% and a negative net margin of 65.46%. Equities analysts expect that NovaBay Pharmaceuticals will post -0.41 EPS for the current year.
Hedge Funds Weigh In On NovaBay Pharmaceuticals
NovaBay Pharmaceuticals Company Profile
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
See Also
- Five stocks we like better than NovaBay Pharmaceuticals
- Short Selling: How to Short a Stock
- 3 Stocks Leading the U.S. Agriculture Comeback
- Low PE Growth Stocks: Unlocking Investment Opportunities
- How to Use Put Debit Spreads to Profit From Falling Stocks
- What Does Downgrade Mean in Investing?
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.